Funder
Agenzia Italiana del Farmaco
AIFA
Italian Association for Cancer Research
AIRC
Veneto Institute of Oncology
Reference25 articles.
1. Trastuzumab containing regimens for early breast cancer;Moja;Cochrane Database Syst Rev,2012
2. Escalation and de-escalation in HER2 positive early breast cancer;Dieci;Curr Opin Oncol,2018
3. PERSEPHONE: 6 versus 12 months (m) of adjuvant trastuzumab in patients (pts) with HER2 positive (+) early breast cancer (EBC): randomised phase 3 non-inferiority trial with definitive 4-year (yr) disease-free survival (DFS) results;Earl;J Clin Oncol,2018
4. PHARE trial investigators.6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial;Pivot;Lancet Oncol,2013
5. Effect of adjuvant trastuzumab for a duration of 9 weeks vs 1 year with concomitant chemotherapy for early human epidermal growth factor receptor 2-positive breast cancer: the SOLD randomized clinical trial;Joensuu;JAMA Oncol,2018
Cited by
64 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献